why choose us

Clinical Trials Search

Showing 15,760 of 132,963 result(s)
Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

Status: Completed

Condition: Atrial Fibrillation

Interventions: Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable card

Date: 2023-01-30

Effects of Administration of SCFA in Rheumatoid Arthritis Inadequate Responders

Status: Completed

Condition: Rheumatoid Arthritis

Interventions: Participants will self-administer the oral Short Chain Fatty Acid (SCFA) Butyrate supplement three times daily with meals for up to 2 months.
The

Date: 2023-01-30

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Status: Completed

Condition: Atopic Dermatitis

Interventions: Part A: Single topical dose

Date: 2023-01-30

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Status: NOT_YET_RECRUITING

Condition: Prostatic Neoplasms, Castration-Resistant

Interventions: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol

Date: 2023-01-30

Counseling for Harm Reduction and Retention in Medication-assisted Treatment - Cherokee Nation

Status: Completed

Condition: Opioid Use Disorder

Interventions: TAU entails medication to support patients' recovery (i.e., the partial opioid agonist, buprenorophine + naloxone; Suboxone gel films), in-p

Date: 2023-01-30

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Status: Completed

Condition: Solid Tumor, Adult

Interventions: Autologous logic-gated Tmod CAR T-cells

Date: 2023-01-30

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients With Glioblastoma

Status: NOT_YET_RECRUITING

Condition: Glioblastoma

Interventions: Given PO

Date: 2023-01-30

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Status: Completed

Condition: Locally Advanced Solid Tumor

Interventions: TNG462, a selective PRMT5 inhibitor, will be administered orally

Date: 2023-01-30

Hybrid Type I Effectiveness-Implementation Trial of Project nGage

Status: NOT_YET_RECRUITING

Condition: HIV Seropositivity

Interventions: Project nGage ("nGage") is an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote

Date: 2023-01-30

Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial

Status: Completed

Condition: Surgery

Interventions:

Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:

  • Ibuprofen 600 milligram

    Date: 2023-01-30